Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azilsartan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 known ✓ | P30556 | 1/20 | 0.68 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.68 |
| ▸ | EGFR | P00533 | 1/20 | 0.68 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.68 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.68 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.68 |
| ▸ | HTR2C | P28335 | 1/20 | 0.68 |
| ▸ | PPARG | P37231 | 1/20 | 0.68 |
| ▸ | HTR2B | P41595 | 1/20 | 0.68 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.68 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azilsartan SCHEMBL30604716 | 1.00 | AGTR2 (0.68) | AGTR2ABCB11EGFRERBB2CYP3A4 | |
| Azilsartan SCHEMBL7017842 | 0.99 | AGTR2 (0.67) | AGTR2ABCB11EGFRERBB2CYP3A4 | |
| Azilsartan SCHEMBL7017834 | 0.99 | AGTR2 (0.67) | AGTR2ABCB11EGFRERBB2CYP3A4 | |
| SCHEMBL7015607 | 0.93 | ABCB11 (0.59) | AGTR2ABCB11EGFRERBB2CYP3A4 | |
| SCHEMBL5138326 | 0.93 | AGTR1 (0.61) | AGTR2ABCB11EGFRERBB2CYP3A4 | |
| SCHEMBL24209308 | 0.92 | AGTR1 (0.60) | AGTR2ABCB11EGFRERBB2CYP3A4 | |
| Azilsartan SCHEMBL7017839 | 0.92 | AGTR2 (0.57) | AGTR2ABCB11EGFRERBB2CYP3A4 | |
| SCHEMBL7017670 | 0.92 | AGTR2 (0.59) | AGTR2ABCB11EGFRERBB2CYP3A4 | |
| SCHEMBL7015932 | 0.91 | ABCB11 (0.56) | AGTR2ABCB11EGFRERBB2CYP3A4 | |
| SCHEMBL28574033 | 0.89 | ABCB11 (0.55) | AGTR2ABCB11EGFRERBB2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 495 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2329812-B1 | FILM-COATED SCORED TABLET | TAKEDA PHARMACEUTICALS CO (JP) | 2017-09-06 | — | — | EP | claimed |
| WO-2016147120-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE AZILSARTAN | SMILAX LABORATORIES LIMITED (IN) | 2016-09-22 | — | — | WO | claimed |
| US-20160081901-A1 | COMPOSITIONS AND METHODS FOR HAIR GROWTH | WUHAN OPTICS VALLEY BRIDGEBIOMED INTERNATIONAL CORPORATION (CN) | 2016-03-24 | — | — | US | claimed |
| EP-2428202-B1 | Orally disintegrating compositions | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi (TR) | 2015-07-01 | — | — | EP | claimed |
| EP-2586424-B1 | Pharmaceutical combinations comprising an angiotensin II receptor antagonist, hydrochlorothiazide and a disintegrant. | SANOVEL ILAC SANAYI VE TICARET (TR) | 2014-08-13 | — | — | EP | claimed |
| US-8541024-B2 | Film-coated scored tablet | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-09-24 | — | — | US | claimed |
| EP-2394638-B1 | New pharmaceutical combinations | SANOVEL ILAC SANAYI VE TICARET ANONIM SIRKETI (TR) | 2013-05-08 | — | — | EP | claimed |
| EP-2586424-A1 | New pharmaceutical combinations | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2013-05-01 | — | — | EP | claimed |
| EP-1579872-B1 | BODY WEIGHT GAIN INHIBITOR | TAKEDA PHARMACEUTICAL (JP) | 2012-03-28 | — | — | EP | claimed |
| EP-2428202-A2 | Orally disintegrating compositions | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2012-03-14 | — | — | EP | claimed |
| US-5721263-A | ANGIOTENSIN II ANTAGONIST IN COMBINATION WITH DIURETIC OR CALCIUM ANTAGONIST; TREATING HYPERTENSION | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-24 | — | — | US | claimed |
| WO-1997037688-A2 | PHARMACEUTICAL COMBINATION CONTAINING A COMPOUND HAVING ANGIOTENSIN II AND ANTAGONISTIC ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-16 | — | — | WO | claimed |
| EP-0753301-A1 | Combination of benzimidazoles having angiotensin-II antagonistic activity with diuretics | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-01-15 | — | — | EP | claimed |
| US-5583141-A | ADMINISTERING AS THERAPEUTIC AGENTS OF CIRCULATORY DISEASES; AZILSARTAN; ANGIOTENSIN II ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-12-10 | — | — | US | claimed |
| WO-1995001176-A1 | USE OF AN ANGIOTENSIN II ANTAGONIST AS AN OCULAR HYPOTENSIVE AGENT | SENJU PHARMACEUTICAL CO., LTD. (JP) | 1995-01-12 | — | — | WO | claimed |
| EP-0631780-A1 | Use of an angiotensin II antagonist as an ocular hypotensive agent | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-01-04 | — | — | EP | claimed |
| EP-0628313-A1 | Combination of benzimidazoles having angiotensin-II antagonistic activity with dinretics or calcium antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-12-14 | — | — | EP | claimed |
| US-5354766-A | 2-Ethoxy-1-((2'(2,5-dihydro-5-oxo-1,2,4-oxadiazol-3-yl) biphenyl-4-yl)methyl)benzimidazole-7-carboxylic acid; hypotensive agents; CNS activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-10-11 | — | — | US | claimed |
| US-5243054-A | Hypotensive agents, cardiovascular disorders or nervous system disorders | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-09-07 | — | — | US | claimed |
| EP-0520423-A2 | Heterocyclic compounds, their production and use as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-12-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160081901-A1 | COMPOSITIONS AND METHODS FOR HAIR GROWTH | AGTR2, AGTR1, BDKRB2 | AGTR1 2/4885AGTR2 1/4885ABCB11 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.